FDA Brief

Warning letters Drugs

FDA warning letter to

HealthMEDS Inc.

MediumIssued Sep 29, 2021Posted Oct 12, 2021Center for Drug Evaluation and Research | CDER

HealthMEDS Inc., an over-the-counter drug maker, failed to provide FDA-requested records and did not respond to repeated FDA contacts.

What happened

FDA sent an electronic request for records and other information on February 1, 2021, to the contact email in HealthMEDS’s registration file for its over-the-counter drug products, including ProClean-Pure Atomizer Mist 5 mL. The company did not answer that request or FDA’s phone calls, and it also did not respond to a May 6, 2021 follow-up request sent by certified return-receipt mail. FDA said it therefore has no indication of the level of quality assurance for drugs registered as manufactured at the facility.

What FDA found

  1. The company refused to permit access to or copying of records requested by FDA.

    Section 301(e) of the FD&C Act (21 U.S.C. 331(e)); section 704(a)(4) (21 U.S.C. 374(a)(4))
  2. The company did not answer FDA’s February 1, 2021 electronic request for records.

    Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))
  3. The company did not answer FDA’s May 6, 2021 follow-up request sent by certified mail.

    Section 704(a)(4) of the FD&C Act (21 U.S.C. 374(a)(4))

What FDA wants

Respond within 48 hours to confirm or update registration and/or drug listing status and indicate whether you will respond to the records request. If you are no longer manufacturing drugs, delist all drugs using the last lot expiration date as the marketing end date and deregister the facility.

Who should pay attention

  • OTC drug manufacturers and distributors
  • brands selling hand sanitizers or other OTC drugs
  • regulatory teams that manage FDA registration and drug listing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Chongqing Qiancan Technology Co., Ltd.

    Chongqing Qiancan Technology, an API maker in China, refused FDA records requests; FDA placed its drugs on import alert 66-79.

    High risk
  2. Zenzi Pharmaceutical Industries Pvt. Ltd.

    Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.

    High risk
  3. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  4. Gulf States International, Inc.

    Gulf States International refused FDA requests for OTC drug manufacturing records, FDA says.

    Medium